Drug Search Results
More Filters [+]

Lobeline

Alternative Names: lobeline
Latest Update: 2024-10-03
Latest Update Note: News Article

Product Description

Mechanisms of Action: VMAT1 Inhibitor,NIACR Antagonist

Novel Mechanism: Yes

Modality: Small Molecule

Route of Administration: Oral,Sublingual

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: China | Taiwan

Approved Indications: None

Known Adverse Events: None

Company: Yaupon
Company Location:
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Lobeline

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 2: Attention Deficit Disorder with Hyperactivity

Phase 1: Amphetamine-Related Disorders|Methamphetamine Dependence

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

R43MH081553

P2

Completed

Attention Deficit Disorder with Hyperactivity

2010-01-01

NIDA-CPU-0007-1

P1

Unknown status

Amphetamine-Related Disorders

None

NIDA-CPU-0012-1

P1

Unknown status

Methamphetamine Dependence|Amphetamine-Related Disorders

None

NIDA-CPU-0009-1

P1

Unknown status

Amphetamine-Related Disorders|Methamphetamine Dependence

None

Recent News Events